Assessment of Grazax® Treatment Compliance

ALK-Abelló

Status and phase: Completed; Phase 3

Conditions: Allergy

Treatments: Biological: ALK Grass tablet - use of compliance device

Study type: Interventional

Funder types: Industry

Identifiers

NCT00293046

GT-10

Details and patient eligibility

About

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Grass pollen induced rhinoconjunctivitis
• Males and females, 18-65 years of age
• Positive skin prick test

Exclusion criteria

• Previous treatment with grass pollen allergen